Atossa Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on May 7, 2026. Atossa Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Seattle, Washington. As of the record date of March 19, 2026, there were 8,611,361 shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
All proposals presented at the Annual Meeting were approved by stockholders. The specific results were as follows:
- Election of Directors: All three Class II nominees (Stephen J. Galli, M.D., Richard I. Steinhart, and Tessa Cigler, M.D., M.P.H.) were elected. Broker non-votes totaled 2,222,160 for each nominee.
- Ratification of Independent Auditor: Ernst & Young LLP was ratified for the fiscal year ending December 31, 2026, with 3,714,889 votes for and 370,496 votes against.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 2:1 and 20:1 if deemed necessary by the Board. This proposal received 2,336,815 votes for and 1,866,873 votes against.
- Advisory Vote on Executive Compensation: The compensation of named executive officers was approved on a non-binding basis with 1,530,390 votes for and 444,616 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the authorization of a potential reverse stock split.
Key Facts for Investor Verification
- Verify the Board's subsequent determination on whether to execute the authorized reverse stock split (2:1 to 20:1 ratio).
- Note the significant number of broker non-votes (2,222,160) on director elections and executive compensation, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the implementation timeline for the ratified independent auditor, Ernst & Young LLP, for the 2026 fiscal year.